ANDREW J. WEISENFELD, Senior Managing Director
Andrew has been an investment banker since 1989. Andrew became a senior member of the MTS team in January 2008, primarily responsible for the development of the life sciences and medical technology practices. Prior to joining, Andrew was a Managing Director in Banc of America Securities' Corporate and Investment Banking Healthcare Group. Andrew co-led the firm's life sciences practice, providing capital raising and strategic advisory services to both publicly traded and private companies. Prior to joining Bank of America in 2003, Andrew was a Managing Director at JP Morgan, leading its Healthcare M&A business across all sectors of healthcare since 1999. Andrew joined Chase Securities, a predecessor company to JP Morgan, in 1997. Prior to joining Chase, Andrew spent over five years in the M&A Group at Merrill Lynch. Throughout his career, Andrew has worked on a range of advisory transactions including acquisitions, sale transactions and strategic relationships. Selected life sciences transactions include Reata's strategic partnership with Abbott Labs, the merger of Trimeris and Synageva, the sale of Trubion to Emergent BioSolutions, Genzyme's acquisition of Bioenvision, the sale of Nabi's Phoslo product and Biologics business to Fresenius and Biotest, respectively, the sale of Corixa to GlaxoSmithKline, the sale of TKT to Shire, Genzyme's acquisition of Impath, the sale of ALZA to J&J, the sale of BioChem Pharma to Shire, Lundbeck's acquisition of Synaptic, Genta's collaboration with Aventis, and the sale of Gilead's oncology assets to OSI. Andrew has also been responsible for many life sciences financings. Since joining MTS, Andrew has worked on capital market transactions for such companies as NuPathe (IPO), Methylgene, Acadia Pharmaceuticals,Threshold Pharmaceuticals, Oscient Pharmaceuticals (debt restructuring) and Newron. Andrew holds an MBA from The Wharton School at the University of Pennsylvania and a BS from Cornell University.
